Use of Tamoxifen and Aromatase Inhibitors in a Large Population-based Cohort of Women with Breast Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2011 Apr 28

PMID 21522148

Citations 25

Authors

L Huiart

S DellAniello

S Suissa

Affiliations

Soon will be listed here.

Abstract

Background: Non-compliance with oral treatment in oncology is an emerging health issue. For breast cancer (BC) patients, few data are available on compliance and persistence to tamoxifen in younger women and to aromatase inhibitors (AIs) as compared with tamoxifen in older women.

Methods: We constituted a cohort of 13,479 women with BC who received at least one prescription of tamoxifen or AI between 1998 and 2008, in the United Kingdom General Practice Research Database. Days covered by medication and treatment discontinuation were studied. Time to treatment discontinuation was calculated using Kaplan-Meier estimates.

Results: Overall, 18.9% (95% CI: 15.1-23.0) of women on AIs as compared with 31.0% (95% CI: 29.6-32.2) of women on tamoxifen had discontinued their treatments within the first 5 years (P<0.001). This rate raised to 50.7% (95% CI: 43.0-57.9) among the 416 women under 40 years receiving tamoxifen as initial hormonal therapy. Among older women, treatment discontinuation was less frequent for AIs as compared with tamoxifen (P<0.001). Among women on AI therapy, 14% of them (n=374) had switched treatments.

Conclusion: Among older women, the real-life patterns of use of AI show high rates of compliance. In younger women, tamoxifen is prematurely discontinued for half of patients.

Citing Articles

Adherence to adjuvant endocrine therapy after breast cancer in Sweden - a nationwide cohort study in 1-, 3- and 5-year survivors with a focus on regional differences.

De Jong A, von Wachenfeldt A, Nystrom L, Andersson A Acta Oncol. 2024; 63:901-908.

PMID: 39582228 PMC: 11609876. DOI: 10.2340/1651-226X.2024.40575.

Investigation of Factors Affecting Adherence to Adjuvant Hormone Therapy in Early-Stage Breast Cancer Patients: A Comprehensive Systematic Review.

Yang S, Park S, Bae S, Ahn S, Jeong J, Park K J Breast Cancer. 2023; 26(4):309-333.

PMID: 37272247 PMC: 10475712. DOI: 10.4048/jbc.2023.26.e22.

Analysing breast cancer survivors' acceptance profiles for using an electronic pillbox connected to a smartphone application using Seintinelles, a French community-based research tool.

Goetzinger C, Alleaume C, Schritz A, Vrijens B, Preau M, Fagherazzi G Front Pharmacol. 2022; 13:889695.

PMID: 36238564 PMC: 9551449. DOI: 10.3389/fphar.2022.889695.

Assessment of compliance with hormonal therapy in early breast cancer patients with positive hormone receptor phenotype: A single institution study.

Elsamany S, Alghanmi H, Albaradei A, Abdelhamid R, Madi E, Ramzan A Breast. 2022; 62:69-74.

PMID: 35131645 PMC: 9073292. DOI: 10.1016/j.breast.2022.01.017.

Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial.

Alipour S, Abedi M, Saberi A, Maleki-Hajiagha A, Faiz F, Shahsavari S BMC Endocr Disord. 2021; 21(1):169.

PMID: 34416879 PMC: 8377455. DOI: 10.1186/s12902-021-00824-4.

References

Gnerlich J, Deshpande A, Jeffe D, Sweet A, White N, Margenthaler J . Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009; 208(3):341-7. PMC: 3262236. DOI: 10.1016/j.jamcollsurg.2008.12.001. View

Partridge A, Wang P, Winer E, Avorn J . Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003; 21(4):602-6. DOI: 10.1200/JCO.2003.07.071. View

Adami H, Malker B, Holmberg L, Persson I, Stone B . The relation between survival and age at diagnosis in breast cancer. N Engl J Med. 1986; 315(9):559-63. DOI: 10.1056/NEJM198608283150906. View

Ganz P, Greendale G, Petersen L, Kahn B, Bower J . Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol. 2003; 21(22):4184-93. DOI: 10.1200/JCO.2003.04.196. View

McCowan C, Shearer J, Donnan P, Dewar J, Crilly M, Thompson A . Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008; 99(11):1763-8. PMC: 2600703. DOI: 10.1038/sj.bjc.6604758. View

. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472):1687-717. DOI: 10.1016/S0140-6736(05)66544-0. View

Love R . Prospects for antiestrogen chemoprevention of breast cancer. J Natl Cancer Inst. 1990; 82(1):18-21. DOI: 10.1093/jnci/82.1.18. View

Horne R, Weinman J . Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 2000; 47(6):555-67. DOI: 10.1016/s0022-3999(99)00057-4. View

Chung M, Chang H, Bland K, Wanebo H . Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 1996; 77(1):97-103. DOI: 10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.0.CO;2-3. View

10.

Fallowfield L, Leaity S, Howell A, Benson S, Cella D . Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat. 1999; 55(2):189-99. DOI: 10.1023/a:1006263818115. View

11.

Thewes B, Meiser B, Duric V, Stockler M, Taylor A, Stuart-Harris R . What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?. Lancet Oncol. 2005; 6(8):581-8. DOI: 10.1016/S1470-2045(05)70254-0. View

12.

Ruddy K, Mayer E, Partridge A . Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009; 59(1):56-66. DOI: 10.3322/caac.20004. View

13.

Goldhirsch A, Ingle J, Gelber R, Coates A, Thurlimann B, Senn H . Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009; 20(8):1319-29. PMC: 2720818. DOI: 10.1093/annonc/mdp322. View

14.

Partridge A, Avorn J, Wang P, Winer E . Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002; 94(9):652-61. DOI: 10.1093/jnci/94.9.652. View

15.

Lawrenson R, Williams T, Farmer R . Clinical information for research; the use of general practice databases. J Public Health Med. 1999; 21(3):299-304. DOI: 10.1093/pubmed/21.3.299. View

16.

Waterhouse D, Calzone K, Mele C, Brenner D . Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993; 11(6):1189-97. DOI: 10.1200/JCO.1993.11.6.1189. View

17.

Pellegrini I, Sarradon-Eck A, Ben Soussan P, Lacour A, Largillier R, Tallet A . Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients' point of view. Psychooncology. 2009; 19(5):472-9. DOI: 10.1002/pon.1593. View

18.

Mor V, Malin M, Allen S . Age differences in the psychosocial problems encountered by breast cancer patients. J Natl Cancer Inst Monogr. 1994; (16):191-7. View

19.

Chlebowski R . Clinical trial presentations, agency guidelines, and oncology practice: findings from the arimidex, tamoxifen, alone or in combination trial. Clin Breast Cancer. 2008; 8(4):343-6. DOI: 10.3816/CBC.2008.n.039. View

20.

Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G . Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006; 7(8):633-43. DOI: 10.1016/S1470-2045(06)70767-7. View